Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-22
2008-07-22
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S157000, C546S158000, C546S290000, C544S105000, C548S165000, C564S090000, C514S230500, C514S345000, C514S367000, C514S604000
Reexamination Certificate
active
07402598
ABSTRACT:
The present invention relates to compounds of formula (I) as defined herein and salts or solvates thereof. Processes for preparing these compounds and pharmaceutical formulations containing them are also disclosed, as well as methods for the prophylaxis of treatment of a clinical condition using such compounds.
REFERENCES:
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4730008 (1988-03-01), Skidmore et al.
patent: 4853381 (1989-08-01), Finch et al.
patent: 4853382 (1989-08-01), Skidmore et al.
patent: 4908386 (1990-03-01), Finch et al.
patent: 4937268 (1990-06-01), Skidmore et al.
patent: 4963564 (1990-10-01), Skidmore et al.
patent: 4990505 (1991-02-01), Skidmore et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 4997986 (1991-03-01), Mitchell et al.
patent: 5066678 (1991-11-01), Finch et al.
patent: 5099068 (1992-03-01), Mitchell et al.
patent: 5109023 (1992-04-01), Mitchell et al.
patent: 5283262 (1994-02-01), Mitchell et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 6395738 (2002-05-01), Ohshima et al.
patent: 6514996 (2003-02-01), Ohshima et al.
patent: 6716987 (2004-04-01), Ohshima et al.
patent: 2002/0012829 (2002-01-01), Yamahira et al.
patent: 3524990 (1986-01-01), None
patent: 4028398 (1992-03-01), None
patent: 69715 (1983-01-01), None
patent: 0162576 (1985-11-01), None
patent: 0220054 (1987-04-01), None
patent: 220878 (1987-05-01), None
patent: 223410 (1987-05-01), None
patent: 286242 (1988-10-01), None
patent: 303465 (1989-02-01), None
patent: 317206 (1989-05-01), None
patent: 416951 (1991-03-01), None
patent: 2064336 (1981-06-01), None
patent: 2129691 (1984-05-01), None
patent: 2140800 (1984-12-01), None
patent: 2159151 (1985-11-01), None
patent: 2162842 (1986-02-01), None
patent: 2169265 (1986-07-01), None
patent: 2178965 (1987-02-01), None
patent: 2230523 (1990-10-01), None
patent: 416951 (1991-09-01), None
patent: 2242134 (1991-09-01), None
patent: 95/01170 (1995-01-01), None
patent: WO 95/19336 (1995-07-01), None
patent: 99/16766 (1999-04-01), None
patent: 99/47505 (1999-09-01), None
patent: 01/13953 (2001-03-01), None
Thornber, C.W.; Isosterism and Molecular Modification in Drug Design; Chemical Society Reviews; 1979; vol. 8, Iss. 4; pp. 563-580;.
Iakovidis, D. et al.; Synthesis and beta-andrenoceptor agonist properties of (+/-)-1-(3′, 4′-dihydroxyphenoxy)-3-(3″, 4″-dimethooxyphenyl)ethylamino-2-propanol hydrochloride, (+/-)-RO363.HCI,and the (2S)-(-)-isomer; European Journal of Medicinal Chemistry; 1999; vol. 34, No. 6; pp. 539-548;.
Fuji et al.; Novelphosphodiesterase 4 inhibitor T-440 reverse and prevents human bronchial contraction induced by allergen.; Journal of Pharmacology and Experimental Therapeutics; 1998; vol. 284, No. 1; pp. 162-169;.
Landells, et al.; Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294 inhibits ex-vivo agonist-induced-cell activation.; European Respiratory Journal (/annu Cong Eur Resp Soc, Geneva); 1998; vol. 12, Suppl. 28; Abst P2393;.
McHale, M.M.et al.; Expression of Human recombinant cAMP Phosphodiesterase Isozyme IV Reverses Growth Arrest Phenotypes in Phosphodiesterase-Deficient Yeast; Molecular Pharmacology; 1991; vol. 39; pp. 109-113.
Nicholson, C. D, et al.; Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes; Trends in Pharmacological Sciences; 1991; vol. 12; pp. 19-27;.
Torphy, T.J., et al.; Role of Cyclic Nucleotide Phosphodiesterase Isozymes in Intact Canine Trachealis; Molecular Pharmacology; 1991; vol. 39; pp. 376-384;.
Biggadike Keith
Coe Diane Mary
Holmes Duncan Stuart
Looker Brian Edgar
Aulakh Charanjit S.
Glaxo Group Limited
Smith Robert J.
LandOfFree
Arylethanolamine β 2 -adrenoreceptor agonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylethanolamine β 2 -adrenoreceptor agonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylethanolamine β 2 -adrenoreceptor agonist compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764899